Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis

Area of Science:

• Neurology
• Radiology
• Immunology

Background:

• Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
• Assessing disease activity and lesion development in MS is crucial for patient management.
• Gadolinium-DTPA (Gd-DTPA) enhanced magnetic resonance imaging (MRI) is a key tool for visualizing blood-brain barrier (BBB) disruption.

Purpose of the Study:

• To evaluate the utility of serial Gd-DTPA enhanced MRI in detecting and characterizing new and active lesions in multiple sclerosis.
• To assess the temporal dynamics of lesion enhancement and BBB permeability in MS patients over time.
• To determine if Gd-DTPA enhancement can serve as a reliable marker for monitoring disease activity and therapeutic efficacy in MS.

Main Methods:

• Serial Gd-DTPA enhanced MRI scans were performed on 9 patients diagnosed with multiple sclerosis.
• Lesion enhancement patterns were analyzed across three time points: initial scan, 3-5 weeks, and 6 months.
• New lesions identified on unenhanced scans were assessed for Gd-DTPA enhancement.

Main Results:

• Enhancing lesions were observed in 7 of 9 patients during acute relapse, with most being asymptomatic.
• Persistent enhancement was limited, with only 12/54 lesions enhancing at 3-5 weeks and none at 6 months.
• Gd-DTPA enhancement was detected in all new lesion areas identified on unenhanced scans and in some older lesions, indicating active BBB breakdown.

Conclusions:

• Blood-brain barrier impairment is a consistent feature of new MS lesions detected by MRI.
• Gd-DTPA is a valuable marker for identifying new and biologically active lesions in MS.
• Serial Gd-DTPA enhanced MRI shows promise for monitoring therapeutic interventions in multiple sclerosis clinical trials.